ANEB vs. RVPH, LPTX, SLS, AFMD, TPST, LFVN, VTVT, HOOK, JAGX, and CRVS
Should you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Reviva Pharmaceuticals (RVPH), Leap Therapeutics (LPTX), SELLAS Life Sciences Group (SLS), Affimed (AFMD), Tempest Therapeutics (TPST), LifeVantage (LFVN), vTv Therapeutics (VTVT), Hookipa Pharma (HOOK), Jaguar Health (JAGX), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical preparations" industry.
Reviva Pharmaceuticals (NASDAQ:RVPH) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment.
In the previous week, Reviva Pharmaceuticals had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 9 mentions for Reviva Pharmaceuticals and 8 mentions for Anebulo Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 0.90 beat Anebulo Pharmaceuticals' score of 0.85 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the news media.
Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Reviva Pharmaceuticals has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -0.98, indicating that its stock price is 198% less volatile than the S&P 500.
63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 31.8% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 85.9% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Reviva Pharmaceuticals received 9 more outperform votes than Anebulo Pharmaceuticals when rated by MarketBeat users. Likewise, 88.89% of users gave Reviva Pharmaceuticals an outperform vote while only 87.50% of users gave Anebulo Pharmaceuticals an outperform vote.
Reviva Pharmaceuticals' return on equity of -109.40% beat Anebulo Pharmaceuticals' return on equity.
Reviva Pharmaceuticals currently has a consensus price target of $16.33, indicating a potential upside of 855.17%. Anebulo Pharmaceuticals has a consensus price target of $6.67, indicating a potential upside of 201.66%. Given Anebulo Pharmaceuticals' higher possible upside, equities analysts clearly believe Reviva Pharmaceuticals is more favorable than Anebulo Pharmaceuticals.
Summary
Reviva Pharmaceuticals beats Anebulo Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Anebulo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anebulo Pharmaceuticals Competitors List
Related Companies and Tools
